thromboDx BV has licensed the intellectual property rights to a broad patent portfolio covering the use of platelets as unique source of disease specific nucleic acids. thromboDx BV has an aggressive strategy in pursuing new intellectual property where and when possible. Additionally thromboDx BV has developed a large body of know-how that relates to platelet-powered diagnostics.


thromboDx BV focuses on the development of molecular diagnostic tests. We combine in-house development of diagnostic tests in areas and indications of strategic interest with a licensing model for non-core areas. To enable this commercial model the company demonstrates applicability, technological and clinical robustness of the platform in validation cohorts.


At this stage of the company, we focus on validation of our proprietary technology in ONCOLOGY, in particular lung cancer (NSCLC) and colorectal cancer (CRC), and brain cancer, prostate cancer, and melanoma. In addition, we consider applications for INFECTIOUS DISEASES and PRENATAL markets.


We seek partners for co-development and commercialization.